Interaction between β2 adrenergic receptor polymorphisms determines the extent of isoproterenol-induced vasodilatation ex vivo

Pharmacogenetics and Genomics

Volumn 17, Issue 10, 2007, Pages 803-811

  Khalaila, Jawad M ^a   Elami, Amir ^a   Caraco, Yoseph ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

2 adrenergic receptor; Desensitization; Genetic polymorphism; Isoproterenol; Organ bath; Vasodilatation

Indexed keywords

ARGININE; BETA 2 ADRENERGIC RECEPTOR; GLUTAMIC ACID; GLUTAMINE; GLYCINE; ISOLEUCINE; ISOPRENALINE; THREONINE;

ADULT; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DNA MODIFICATION; EX VIVO STUDY; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNAL MAMMARY ARTERY; MALE; MOLECULAR INTERACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR RING; VASODILATATION; ARTERY; CODON; DEMOGRAPHY; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; IN VITRO STUDY; MAMMARY GLAND; MIDDLE AGED; PHYSIOLOGY; VASCULARIZATION;

ARTERIES; CODON; DEMOGRAPHY; FEMALE; GENOTYPE; HUMANS; ISOPROTERENOL; MALE; MAMMARY GLANDS, HUMAN; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; VASODILATION;

EID: 34648857531     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3281eb8f07     Document Type: Article

References (36)

1. Meyer UA. Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5:669-676.
2. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352:2211-2221.
3. Johnson JA, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 2003; 13:525-534.
4. Flordellis C, Paris H, Karabinis A, Lymperopoulos A. Pharmacogenomics of adrenoceptors. Pharmacogenomics 2004; 5:803-817.
5. Leineweber K, Buscher R, Bruck H, Brodde OE. Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:1-22.
6. La Rosee K, Huntgeburth M, Rosenkranz S, Bohm M, Schnabel P. The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics 2004; 14:711-716.
7. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117:18-24.
8. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43:381-411.
9. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8:334-339.
10. http://snpper.chip.org Accessed on December 5, 2006.
11. Aynacioglu AS, Cascorbi I, Gungor K, Ozkur M, Bekir N, Roots I, et al. Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the beta2-adrenergic receptor among Turks. Br J Clin Pharmacol 1999; 48:761-764.
12. Xie HG, Stein CM, Kim RB, Xiao ZS, He N, Zhou HH, et al. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 1999; 9:511-516.
13. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33:9414-9419.
14. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13:25-33.
15. Cockcroft JR, Gazis AG, Cross DJ, Wheatley A, Dewar J, Hall IP, et al. Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 2000; 36:371-375.
16. Garovic VD, Joyner MJ, Dietz NM, Boerwinkle E, Turner ST. Beta(2)-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J Physiol 2003; 546:583-589.
17. Hoit BD, Suresh DP, Craft L, Walsh RA, Liggett SB. Beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 2000; 139:537-542.
18. Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, et al. Beta-2 adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 1999; 33:1425-1430.
19. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345:1030-1035.
20. Bruck H, Leineweber K, Beilfuss A, Weber M, Heusch G, Philipp T, et al. Genotype-dependent time course of lymphocyte beta 2-adrenergic receptor down-regulation. Clin Pharmacol Ther 2003; 74:255-263.
21. Makimoto H, Sakaeda T, Nishiguchi K, Kita T, Sakai T, Komada F, et al. Beta2-adrenergic receptor genotype-related changes in cAMP levels in peripheral blood mononuclear cells after multiple-dose oral procaterol. Pharm Res 2001; 18:1651-1654.
22. Bruck H, Leineweber K, Park J, Weber M, Heusch G, Philipp T, et al. Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo. Clin Pharmacol Ther 2005; 78:232-238.
23. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97:10483-10488.
24. Dishy V, Landau R, Sofowora GG, Xie HG, Smiley RM, Kim RB, et al. Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics 2004; 14:517-522.
25. Angus JA, Wright CE. Techniques to study the pharmacodynamics of isolated large and small blood vessels. J Pharmacol Toxicol Methods 2000; 44:395-407.
26. Cooper A, Heagerty AM. Endothelial dysfunction in human intramyocardial small arteries in atherosclerosis and hypercholesterolemia. Am J Physiol 1998; 275:H1482-H1488.
27. Sisto T, Isola J. Incidence of atherosclerosis in the internal mammary artery. Ann Thorac Surg 1989; 47:884-886.
28. Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol 2007; 46:1-9.
29. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (trial on reversing endothelial dysfunction) study. Circulation 1996; 94:258-265.
30. Verhaar MC, Honing ML, van Dam T, Zwart M, Koomans HA, Kastelein JJ, et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 1999; 42:752-760.
31. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88:2149-2155.
32. Suzuki M, Takamisawa I, Yoshimasa Y, Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res Clin Pract 2007; 76:12-17.
33. Ikarashi T, Hanyu O, Maruyama S, Souda S, Kobayashi C, Abe E, et al. Genotype Gly/Gly of the Arg16Gly polymorphism of the beta2-adrenergic receptor is associated with elevated fasting serum insulin concentrations, but not with acute insulin response to glucose, in type 2 diabetic patients. Diabetes Res Clin Pract 2004; 63:11-18.
34. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals. Am J Hypertens 2005; 18:1009-1014.
35. Lembo G, Iaccarino G, Vecchione C, Barbato E, Izzo R, Fontana D, et al. Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm. J Clin Invest 1997; 100:2007-2014.
36. Small KM, Brown KM, Theiss CT, Seman CA, Weiss ST, Liggett SB. An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation. Pharmacogenetics 2003; 13:535-541.